Ang Li

TL;DR: The gut microbiome in liver cirrhosis is characterized by comparing 98 patients and 83 healthy control individuals and on the basis of only 15 biomarkers, a highly accurate patient discrimination index is created and validated on an independent cohort, suggesting microbiota-targeted biomarkers may be a powerful tool for diagnosis of different diseases.

TL;DR: This study is the first to characterise gut microbiome in patients with HCC and to report the successful diagnosis model establishment and cross-region validation of microbial markers for HCC.

TL;DR: In vitro and in vivo investigations demonstrate that the combination of chemotherapy and chemodynamic therapy achieves excellent anticancer efficacy, and systemic toxicity faced by platinum‐based drugs is avoided through this nanoformulation.

TL;DR: The gut microbiome is altered and may be critical for the onset or development of PBC by interacting with metabolism and immunity, and several altered gut bacterial taxa exhibited potential interactions with PBC through their associations with altered metabolism, immunity and liver function indicators.

TL;DR: Gut microbial profile was unique in PC, providing a microbial marker for non-invasive PC diagnosis, and based on 40 genera associated with PC, microbial markers achieves a high classification power with AUC of 0.842.